Research peptidesbpc 157 dosage

BPC-157 Dosage Chart and Calculator: Protocol and Study Doses

BPC-157 dosage chart: units per dose by vial size for the 250-500 mcg common protocol, a calculator, and the doses five small human studies used.

Written bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

Published September 27, 2026Updated September 28, 2026

The short version

BPC-157 has no approved dose because it has no approved product. Clinic and vendor guides most often describe 250-500 mcg by subcutaneous injection, once or twice daily, for a 4-8 week cycle. That is common practice, not a dose any trial or regulator has established. Five small human studies (about 80 people, two known only from meeting abstracts) used daily enemas or one or two injected doses of 2-20 mg instead. A rat tendon study used a much smaller daily microgram-per-kilogram dose for four weeks. None of these numbers is a recommendation.

The common practice protocol is 250-500 mcg subcutaneous, once or twice daily, 4-8 week cycles with a 2-4 week break - not trial-established.
The only human dosing data is five small studies (about 80 people). They used enemas for one to two weeks or one or two injections, not a repeated injection protocol.
The rat dose from a tendon-healing study is a microgram-per-kilogram daily amount and cannot be converted into a human dose.
The dosage chart on this page gives units per dose by vial size, and the calculator does the arithmetic - neither chooses a dose.

BPC-157 has no approved dose, because it has no approved product. This page reports what five small published human studies and one rat study used. It is not a recommendation for what anyone should take. For what the wider evidence shows and BPC-157’s legal status, see the main BPC-157 guide.

US legal status - Research use only

BPC-157 has no FDA-approved product and no approved dose. It is not presently eligible for lawful 503A compounding, per FDA’s July 2026 briefing document.

AU legal status - Not on the ARTG

Schedule 4 (prescription only) under the Poisons Standard, with no registered product on the ARTG.

Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.

BPC-157 dosage: the common protocol

Clinic and vendor dosing guides most often describe 250-500 mcg by subcutaneous injection, once or twice daily, injected near the injury site when possible. The cycle is 4-8 weeks with a 2-4 week break between cycles. This is common practice, not a dose any trial or regulator has established.

Common protocol

What is commonly used, not a dose established in trials. No regulator has set a dose for BPC-157.

Dose per administration: 250-500 mcg
How often: once or twice daily, injected subcutaneously near the injury site when possible
Route: Subcutaneous injection
Cycle length: 4-8 weeks
Break between cycles: 2-4 weeks
Common vial size: 5 mg
Timing: Consistent daily time; for local soft-tissue use, placed 2-5 cm from the affected area.
Commonly paired with: TB-500, CJC-1295, Ipamorelin

Sources describe weight-based tiers (roughly 200-300 mcg under 150 lb, 300-400 mcg for 150-200 lb, 400-500 mcg over 200 lb) rather than one fixed number. A 5 mg vial in 2 mL bacteriostatic water is the reconstitution both sources reference (2,500 mcg/mL).

Plan a cycle in the protocol builder or work out injection volume in the dosage calculator.

The common BPC-157 dose is 250-500 mcg, once or twice daily, injected subcutaneously near the injury site when possible. From a 5 mg vial mixed with 2 mL of bacteriostatic water, 400 mcg is 16 units (0.16 mL) on a U-100 insulin syringe.

BPC-157 5 mg vial: units per dose

Full 5 mg vial page: mixing, doses per vial, how long it lasts →

Water added	Concentration	1 unit =	250 mcg	400 mcg	500 mcg
1 mL	5 mg/mL	50 mcg	5 units	8 units	10 units
2 mL	2.5 mg/mL	25 mcg	10 units	16 units	20 units
3 mL	1.67 mg/mL	16.67 mcg	15 units	24 units	30 units

BPC-157 10 mg vial: units per dose

Full 10 mg vial page: mixing, doses per vial, how long it lasts →

Water added	Concentration	1 unit =	250 mcg	400 mcg	500 mcg
1 mL	10 mg/mL	100 mcg	2.5 units	4 units	5 units
2 mL	5 mg/mL	50 mcg	5 units	8 units	10 units
3 mL	3.33 mg/mL	33.33 mcg	7.5 units	12 units	15 units

All BPC-157 vial sizes: 5 mg · 10 mg · 20 mg · 40 mg

Units are on a standard U-100 insulin syringe (100 units = 1 mL), rounded to the nearest half unit - half-unit marks are on 0.3 mL syringes. Water volumes are examples: more water means more units per dose, not more doses per vial. For any other vial or dose, use the calculator below.

How many 5 mg vials a cycle takes

Scenario	Dose	Doses a week	Weeks	Total	5 mg vials
Low end of the common protocol	250 mcg	7	4	7 mg	2
High end of the common protocol	500 mcg	14	8	56 mg	12

Whole vials, rounded up. Plan a cycle with your own numbers in the protocol builder. Keep mixed vials cold and use them within the window in how long reconstituted peptides last; where to inject: subcutaneous injection sites.

BPC-157 doses used in human studies

Five small studies, about 80 people dosed in all, make up the entire published human dosing record, as inventoried in FDA’s July 2026 briefing document. Each used a different route for a different problem. Two gave rectal enemas daily for one to two weeks, and three gave one or two injections. None tested a repeated daily injection protocol. The two enema studies exist only as meeting abstracts, so their doses below are as FDA reports them.

Study	Population	Route	Dose	Course
Phase 1 enema study (meeting abstracts, 2002-2003; reported by FDA)	32 healthy volunteers randomised; 24 given BPC-157, 8 placebo	Rectal enema	0.25, 0.5, 1 or 2 mg/kg	Single dose, one-week washout, then once daily for seven days
Ulcerative colitis trial (meeting abstract, 2005; reported by FDA)	53 people with mild to moderate ulcerative colitis, randomised 1:1 to BPC-157 or placebo	Rectal enema	80 mg	Once daily for two weeks
Interstitial cystitis pilot Lee 2024 - Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17., in the references below	12 women, ages 39-76, unresponsive to standard therapy	Intravesical/perilesional injection during cystoscopy	10 mg total	Single procedure
IV safety pilot Lee 2025 - Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24., in the references below	2 healthy adults	Intravenous infusion, 250 cc saline over 1 hour	10 mg (day 1), 20 mg (day 2)	Two consecutive days
Knee-pain chart review Lee 2021 - Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13., in the references below	17 patients enrolled; 16 contacted for follow-up (12 on BPC-157 alone, 4 on BPC-157+TB4)	Intra-articular injection	2-4 mg per injection, as reported by FDA (the abstract gives no dose)	One or two injections, given 6 months-1 year before follow-up

What the three injection studies reported:

Cystitis pilot: complete symptom resolution in 10 of 12 patients after the single injection, with no adverse events.
IV pilot: no measurable change in cardiac, hepatic, renal, thyroid or blood-glucose biomarkers after either infusion, and no side effects in either participant.
Knee-pain review: 14 of 16 contactable patients (87.5%) described relief of knee pain. This was a retrospective chart review, not a controlled trial. Its abstract gives no dose; FDA’s July 2026 briefing document reports 2-4 mg injected into the knee, once or twice.

FDA noted that no serious adverse events appear to have been reported in the five studies. It also noted that the studies were small and short and gave little detail on how safety was monitored.

Doses used in animal studies

A rat Achilles tendon-transection study Biçer 2026 - Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837., in the references below gave BPC-157 at 10 micrograms per kilogram of body weight per day, by intraperitoneal injection, for four weeks after surgery. It used 32 Sprague-Dawley rats (8 per group). The same study also tested TB-500 and a combination arm; see the TB-500 dosage page for that dose.

What is not established

No approved dose exists, for any population, indication, route or duration, because no product has completed FDA review.
No repeated human injection schedule has been studied and published. The only dosing longer than two days in people was by enema, daily for one to two weeks. The three injection studies above used one or two injections or a two-day course. None resembles the daily or twice-daily injection cycles in vendor and forum protocols.
No human half-life is established. The main guide explains why this site does not publish one, so there is no evidence-based basis for any dosing interval.
The common protocol above is current clinic and vendor practice, not a trial finding. Each source is recorded, but no trial or regulator has established that dose.

How to reconstitute BPC-157

The injection volume for a target amount depends on how a specific vial was reconstituted: how much diluent, and what resulting concentration. This page cannot know that for any given vial. The dosage calculator walks through vial strength, diluent volume and target amount. It performs the math; it does not tell you what dose to use.

Who should not use it

No FDA-reviewed contraindication list exists, because BPC-157 has never gone through that review. There is no published human safety data beyond the five tiny studies above. Nothing covers pregnancy, breastfeeding, children, interactions with other medications, or use alongside any diagnosed condition. An unapproved compound with no FDA-reviewed label and no long-term safety record is not something to self-direct around any of that.

BPC-157 side effects and risks

The biggest risk is the size of the gap in the data. No long-term human safety study exists at any dose, no human half-life is established, and material sold as a research chemical carries no regulator-verified purity, identity or concentration. FDA has separately stated it has identified no, or only limited, safety-related information for BPC-157’s proposed routes of administration. It has also flagged possible immunogenicity concerns and unresolved questions about peptide-related impurities and active-ingredient characterisation.

Reconstitution arithmetic for a BPC-157 vial: BPC-157 dosage calculator.

BPC-157 dosage calculator

Preset to a 5 mg vial and 250 mcg, the low end of the common protocol. Enter your own vial size, water and dose to get the syringe units to draw.

Your vial

Peptide in vial (mg)

Printed on the vial. There is no standard size - enter what yours says.

Bacteriostatic water added (mL)

This changes how much you draw - never how many doses the vial holds.

Desired dose (mcg)

Syringe scale

100 units per mL. 1 unit = 0.01 mL. This is what almost every insulin syringe sold is, in every barrel size.

Barrel size

Capacity only. A 1 mL U-100 syringe holds 100 units - the scale decides that, not the barrel.

Draw this much

10units

= 0.1 mL on a 1 mL U-100 syringe

Concentration: 2,500 mcg/mL
Exact volume: 0.1 mL
Dose you actually get: 250 mcg
Doses per vial(unaffected by water volume): 20

Where to buy BPC-157 for research

Each vendor is checked against my vendor checklist.

1.Next Level PharmFeatured
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
- Takes card payment
$48.99as of 3 October 2026
View product →My Next Level Pharm review
2.Spartan Peptides
10 mg vial
- No FDA warning letter found
- Names its testing lab
$199.00as of 3 October 2026
View product →My Spartan Peptides review
3.BioEdge Research Labs
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
$49.00as of 3 October 2026
View product →My BioEdge Research Labs review

BPC-157 capsules

Taken by mouth, and a different product from the vial: ask for a COA for the capsule batch.

BioEdge Research Labs: BPC-157 arginate salt, 500 mcg capsules, 60 count$129.00 as of 3 October 2026 View →

Compare every checked vendor for BPC-157 →

See all vendors and how they compare →

Common questions

What is the usual BPC-157 dose?

Clinic and vendor dosing guides most often describe 250-500 mcg by subcutaneous injection, once or twice daily, near the injury site when possible. The cycle is 4-8 weeks with a 2-4 week break. That is common practice reported by clinic and vendor pages, not a dose established by any trial or regulator. See the next question for what the small published human studies used instead.

What dose of BPC-157 have human studies used?

FDA's July 2026 briefing document counts five small published studies, about 80 people dosed in all; two exist only as meeting abstracts. A placebo-controlled phase 1 study gave healthy volunteers enemas of 0.25-2 mg/kg: a single dose, then, after a week's break, seven daily doses. A randomised trial in ulcerative colitis gave an 80 mg enema or placebo once daily for two weeks. A pilot gave 12 women with interstitial cystitis a single intravesical injection totalling 10 mg during one cystoscopy. A safety pilot infused 2 healthy adults with 10 mg intravenously on day one and 20 mg on day two, each over one hour. A retrospective chart review of 17 knee-pain patients describes injections into the knee. Its abstract gives no dose, but FDA reports 2-4 mg per injection, one or two injections.

Is there an FDA-approved BPC-157 dose?

No. BPC-157 has no FDA-approved product, no approved indication, and no dose established as safe or effective by any regulator. The figures on this page are what specific small studies used in their own participants, not a recommendation.

What dose was used in animal studies?

A rat Achilles tendon study gave BPC-157 at 10 micrograms per kilogram of body weight per day, by intraperitoneal injection, for four weeks after surgery. That is a rat dose in a specific injury model. It is not a human dose, and there is no accepted method for converting it into one.

How do I work out reconstitution and injection volume?

That is arithmetic about a specific vial and diluent, not a dosing decision, and this page cannot know your vial. Use the dosage calculator to work through concentration and draw volume for whatever amount you are looking at. It does the math; it does not tell you what dose to use.

Who should not use BPC-157?

No FDA-reviewed contraindication list exists, because no such review has happened. There is no long-term human safety data at all. Anyone pregnant, breastfeeding, immunocompromised, on other medications, or with any diagnosed medical condition has no regulator-reviewed information to weigh a decision against.

What are the main risks?

The main risk is the absence of data. No long-term human safety study exists, no human half-life has been established, and material sold as a research chemical carries no verified purity, identity, or concentration. FDA has separately flagged possible immunogenicity concerns and unresolved questions about peptide-related impurities for compounds in this class.

When should I stop and get medical care?

Get emergency care (call 911 in the US) for a severe allergic reaction, chest pain, severe injection-site infection, or any symptom that feels dangerous. Call Poison Control at 1-800-222-1222 if you have taken an unknown or excessive amount of anything sold as BPC-157. None of this is a substitute for a clinician who knows your history.

References (5 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.